why choose us

First received: June 24, 2023

Clinical Trial: Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: SCLC,Extensive Stage

Study Type: OBSERVATIONAL


Official Title: Molecular Subtyping of Extensive Stage Small Cell Lung Cancer and Relevent Clinical Significance

Brief Summary: To validate the predictive value of transcriptome-based molecular subtyping of extensive stage small cell lung cancer (SCLC) for the efficacy of programmed death-1(PD-1)/programmed death-ligand1(PD-L1) inhibitor in the first line setting; to explore the differences of immune microenvironment between different SCLC subtypes to reveal the mechanisms of immunotherapy resistance of SCLC

Read more